Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365835 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL18762322 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL3871093 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1365591 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1419528 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL24678064 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL7545592 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL5386843 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL318699 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1363586 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4304655-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| CN-117202936-A | Glucagon-like peptide compounds | 诺华股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022224164-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022189859-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | ALDH1A1 634/4885MAPK1 4777/4885L3MBTL1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.